Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With...
Seborrheic KeratosisThis is a first-in-humans adaptive design open label trial to explore the safety and efficacy of SM-020. Multiple dosing cohorts will be enrolled. The first cohort will have a two-week treatment period of twice daily applications followed by a four-week follow-up period. Based on the results at any time from the first and subsequent cohorts, additional cohorts will explore different dosing regimens.
A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic...
Seborrheic KeratosisThe primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.
An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses
Seborrheic KeratosisThis study is an open-label study designed to evaluate subject's satisfaction after treatment of seborrheic keratoses with A-101 40%.
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
Seborrheic KeratosisThe main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.
Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study
Lesion SkinSeborrheic Keratosis2 morePrimary study objective is to evaluate the optimization of Nano-Pulse Stimulation (NPS) energy settings for lesion clearance of Seborrheic Keratosis (SKs) from off-facial areas of healthy adults.
Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis
Seborrheic Keratosis (SK)Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on the back of subjects.
Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With...
Seborrheic KeratosisThis study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in patients with Seborrhoeic Keratosis on non-head locations. The secondary endpoint is to investigate the efficacy of PEP005 Gel, 0.05% when administered for up to three consecutive days to Seborrhoeic Keratosis on non-head locations.
Dermatosis Papulosa Nigra
Facial DermatosesSeborrheic KeratosesDPN is a disorder among darkly pigmented patients, manifested by small, benign, variants of seborrheic keratoses, predominantly on the face. The purpose of this study is to determine the efficacy of a 585 nm PDL for the treatment of Dermatosis Papulosa Nigra, and compare it to therapy with curettage (scraping the lesions off) and electrodesiccation (burning the lesions off).
Study of A-101 for the Treatment of Seborrheic Keratosis
Seborrheic KeratosisThe purpose of this study is to evaluate the safety and dose-response of 2 concentrations of A-101 versus a vehicle control in the treatment of seborrheic keratosis.
An Open-Label Safety Study of A-101 Solution
Seborrheic KeratosisThis is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.